Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Verducatib (BI 1291583) 4-week multiple ascending dose study in healthy volunteers
NCT04866160Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2021
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of verducatib in bronchiectasis (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Number of subjects with drug-related Adverse Events up to 77 days. Started May 2021; status: completed.
02
Drugs
verducatib
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on NCT04866160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04866160.